The global CRISPR-based POC diagnostics market size was estimated at USD 502.64 million in 2024 and is projected to reach USD 1.78 billion by 2033, growing at a CAGR of 15.41% from 2025 to 2033. The market is expanding as diagnostic capabilities shift closer to the point of care, supported by broader availability of testing in regions with limited healthcare infrastructure.
Cost-effectiveness, high accuracy, and ease of use propel adoption across healthcare systems globally. Strategic partnerships are bringing innovations into the market, specifically in underserved settings. For instance, in August 2023, Crisprbits partnered with Molbio Diagnostics Limited to launch CRISPR-based point-of-care tests to provide cost-effective, innovative, and highly accurate diagnostic solutions while expanding market opportunities and transforming point-of-care diagnostics.
Furthermore, the increasing prevalence of infectious diseases is a major factor propelling the growth of the market. The global burden of infectious conditions such as influenza, tuberculosis, viral hepatitis, and sexually transmitted infections (STIs) has risen steadily, creating an urgent need for rapid, accurate, and affordable diagnostic solutions. In February 2025, the WHO noted that seasonal influenza continues to pose a significant global health burden, with an estimated one billion cases reported annually, including 3-5 million cases of severe illness. The infection is responsible for 290,000 to 650,000 respiratory deaths each year, underscoring its substantial impact on public health systems worldwide. Significantly, 99% of influenza-related lower respiratory tract infection deaths among children under five occur in developing countries, highlighting stark inequalities in healthcare access and outcomes. Moreover, the WHO stated in September 2025 that every day, more than 1 million treatable sexually transmitted infections (STIs) are acquired in people aged 15 to 49 worldwide, with the majority of them asymptomatic. In 2022, an estimated 8 million adults aged 15 to 49 were infected with syphilis.
In addition, the market is expanding rapidly due to the increasing global burden of genetic diseases and the growing demand for rapid, accurate, and cost-effective testing. Traditional PCR and RT-PCR methods, although precise, require sophisticated equipment, trained personnel, and lengthy turnaround times, which limit their utility in resource-constrained and decentralized settings. CRISPR/Cas systems (Cas9, Cas12, and Cas13) offer unparalleled sensitivity, specificity, and programmability, enabling the detection of cancers and genetic variants with single-nucleotide resolution within an hour. Platforms like SHERLOCK and DETECTR have achieved attomolar sensitivity with simple lateral flow or fluorescence readouts, making them excellent candidates for point-of-care applications. CRISPR diagnostics, which combine molecular precision with operational simplicity and scalability, are reshaping the global diagnostics landscape and driving adoption in hospitals, clinics, and decentralized testing programs.
Moreover, the growing global urgency to address antimicrobial resistance (AMR), which has become one of the most important challenges in modern healthcare, is boosting the demand for the CRISPR-based POC diagnostics. Hospitals and healthcare systems worldwide are under increasing pressure to rapidly detect and contain antibiotic-resistant infections, thereby preventing costly outbreaks and improving patient outcomes. CRISPR-based diagnostic platforms offer a compelling value proposition by delivering fast, highly accurate, and easy-to-use testing solutions that reduce reliance on centralized laboratory facilities. These technologies enable clinicians to make early and targeted treatment decisions, minimizing the misuse of antibiotics and optimizing resource utilization. Their portability and scalability make them particularly attractive for deployment in resource-limited settings and point-of-care environments. By combining precision, speed, and accessibility, CRISPR diagnostics are revolutionizing the infectious disease diagnostics market and establishing new benchmarks for efficiency in clinical decision-making. For instance, in February 2025, Crisprbits (India) developed PathCrisp, a molecular diagnostic platform that uses CRISPR technology to detect antibiotic resistance in hospital-acquired infections. The technology is intended to allow early identification of AMR, a major worldwide health concern, particularly in intensive care units (ICUs).
This product will be delivered within 1-3 business days.
Cost-effectiveness, high accuracy, and ease of use propel adoption across healthcare systems globally. Strategic partnerships are bringing innovations into the market, specifically in underserved settings. For instance, in August 2023, Crisprbits partnered with Molbio Diagnostics Limited to launch CRISPR-based point-of-care tests to provide cost-effective, innovative, and highly accurate diagnostic solutions while expanding market opportunities and transforming point-of-care diagnostics.
Furthermore, the increasing prevalence of infectious diseases is a major factor propelling the growth of the market. The global burden of infectious conditions such as influenza, tuberculosis, viral hepatitis, and sexually transmitted infections (STIs) has risen steadily, creating an urgent need for rapid, accurate, and affordable diagnostic solutions. In February 2025, the WHO noted that seasonal influenza continues to pose a significant global health burden, with an estimated one billion cases reported annually, including 3-5 million cases of severe illness. The infection is responsible for 290,000 to 650,000 respiratory deaths each year, underscoring its substantial impact on public health systems worldwide. Significantly, 99% of influenza-related lower respiratory tract infection deaths among children under five occur in developing countries, highlighting stark inequalities in healthcare access and outcomes. Moreover, the WHO stated in September 2025 that every day, more than 1 million treatable sexually transmitted infections (STIs) are acquired in people aged 15 to 49 worldwide, with the majority of them asymptomatic. In 2022, an estimated 8 million adults aged 15 to 49 were infected with syphilis.
In addition, the market is expanding rapidly due to the increasing global burden of genetic diseases and the growing demand for rapid, accurate, and cost-effective testing. Traditional PCR and RT-PCR methods, although precise, require sophisticated equipment, trained personnel, and lengthy turnaround times, which limit their utility in resource-constrained and decentralized settings. CRISPR/Cas systems (Cas9, Cas12, and Cas13) offer unparalleled sensitivity, specificity, and programmability, enabling the detection of cancers and genetic variants with single-nucleotide resolution within an hour. Platforms like SHERLOCK and DETECTR have achieved attomolar sensitivity with simple lateral flow or fluorescence readouts, making them excellent candidates for point-of-care applications. CRISPR diagnostics, which combine molecular precision with operational simplicity and scalability, are reshaping the global diagnostics landscape and driving adoption in hospitals, clinics, and decentralized testing programs.
Moreover, the growing global urgency to address antimicrobial resistance (AMR), which has become one of the most important challenges in modern healthcare, is boosting the demand for the CRISPR-based POC diagnostics. Hospitals and healthcare systems worldwide are under increasing pressure to rapidly detect and contain antibiotic-resistant infections, thereby preventing costly outbreaks and improving patient outcomes. CRISPR-based diagnostic platforms offer a compelling value proposition by delivering fast, highly accurate, and easy-to-use testing solutions that reduce reliance on centralized laboratory facilities. These technologies enable clinicians to make early and targeted treatment decisions, minimizing the misuse of antibiotics and optimizing resource utilization. Their portability and scalability make them particularly attractive for deployment in resource-limited settings and point-of-care environments. By combining precision, speed, and accessibility, CRISPR diagnostics are revolutionizing the infectious disease diagnostics market and establishing new benchmarks for efficiency in clinical decision-making. For instance, in February 2025, Crisprbits (India) developed PathCrisp, a molecular diagnostic platform that uses CRISPR technology to detect antibiotic resistance in hospital-acquired infections. The technology is intended to allow early identification of AMR, a major worldwide health concern, particularly in intensive care units (ICUs).
Global CRISPR-based POC Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global CRISPR-based POC diagnostics market report based on product, technology, application, end-use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Instruments/Devices
- Assay Kits and Reagents
- Software and Connectivity Platforms
Technology Outlook (Revenue, USD Million, 2021-2033)
- Cas9-Based
- Cas12-Based (DETECTR Technology)
- Cas13-Based (SHERLOCK Technology)
- Other Emerging Cas Systems
Application Outlook (Revenue, USD Million, 2021-2033)
- Infectious Disease Diagnostics
- Genetic Disorder Testing
- Oncology Diagnostics
- Antimicrobial Resistance (AMR) Testing
- Other Applications
End-use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals and Clinics
- Diagnostic Laboratories
- Homecare / At-Home Testing
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. CRISPR-based POC Diagnostics Market: Methodology and Scope
Chapter 2. CRISPR-based POC Diagnostics Market: Executive Summary
Chapter 3. CRISPR-based POC Diagnostics Market Variables, Trends, & Scope
Chapter 4. CRISPR-based POC Diagnostics Market: Product Estimates & Trend Analysis
Chapter 5. CRISPR-based POC Diagnostics Market: Technology Estimates & Trend Analysis
Chapter 6. CRISPR-based POC Diagnostics Market: Application Estimates & Trend Analysis
Chapter 7. CRISPR-based POC Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 8. CRISPR-based POC Diagnostics Market: Regional Business Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The key companies profiled in this CRISPR-based POC Diagnostics market report include:- Mammoth Biosciences, Inc.
- OraSure Technologies, Inc. (Sherlock Biosciences)
- Caspr Biotech
- GenScript
- Integrated DNA Technologies, Inc.
- Synthego
- Revvity Discovery Limited
- Twist Bioscience
- Crisprbits
- Danaher Corporation (Cepheid)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | November 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 502.64 Million |
| Forecasted Market Value ( USD | $ 1780 Million |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
